



Qbrexza™ (glycopyrronium) cloth

A Guide Through the Prior Authorization Process

Cover My Meds is an online portal where physician offices and pharmacies can find and submit Prior Authorization (PA) forms for any drug under any insurance plan. Their streamlined approach to the PA/Medical Exception (ME) process digitally connects providers, pharmacists, and payers.

The PA/ME process can be initiated by either your office or the pharmacy. Please see inside for steps to complete a Physician/Office- and a Pharmacy-Initiated PA/ME.

Physician Office Initiated

Offices can initiate and complete PA/ME requests to the payer electronically. This results in quick coverage determinations, usually under 24 hours. Patients are more likely to fulfill their QBREXZA prescription without delay at the pharmacy.

How to complete a Physician/Office-initiated PA/ME:

1. Log in to or create your free account at covermymeds.com
2. Click on “New Request”
3. Fill in patient and medical details (see right side for the most common PA/ME criteria for QBREXZA)
4. Click one button to electronically submit the request to the patient’s plan for determination

Health plans commonly require the following criteria to be met prior to providing coverage for QBREXZA to ensure use in the appropriate patient population:

	Please confirm the patient's diagnosis: <input type="radio"/> L74.510 Primary focal hyperhidrosis, axilla <input type="radio"/> Other
	Has the patient tried and failed an Rx strength antiperspirant (ie, Drysol) or clinical-strength over-the-counter (OTC) antiperspirant? <input type="radio"/> Yes <input type="radio"/> No
	Is the patient 9 years of age or older? <input type="radio"/> Yes <input type="radio"/> No
	Has the patient experienced significant interference with their ability to perform age-related activities of daily life? <input type="radio"/> Yes <input type="radio"/> No

INDICATION

QBREXZA is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications: QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).

WARNINGS AND PRECAUTIONS

Worsening of Urinary Retention: QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

WARNINGS AND PRECAUTIONS (cont'd)

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

ADVERSE REACTIONS

The most common adverse reactions seen in $\geq 2\%$ of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat (2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.

Please [click here](#) for Full Prescribing Information and visit QBREXZA.com for more information.

Qbrexza™
(glycopyrronium) cloth

Pharmacy Initiated

How to complete a pharmacy-initiated PA/ME request:

When a pharmacy starts a PA/ME request for one of your patients, you will receive a fax with a key to access it.

1. Log in to or create your free account at covermymeds.com
2. Click “Enter Key” on your CoverMyMeds dashboard
3. Enter the key, patient’s last name, and date of birth indicated on the fax. Most of the request will already be completed
4. Fill in any remaining clinical fields (see previous page for the most common PA/ME criteria for QBREXZA) and click “Send to Plan”
5. Mark determinations directly in your CoverMyMeds account. The pharmacy will be notified of the outcome once it’s determined by the plan

IMPORTANT SAFETY INFORMATION (cont’d)

DRUG INTERACTIONS

Anticholinergics: Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

INSTRUCTIONS FOR ADMINISTERING QBREXZA

Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Lactation: There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

Renal Impairment: The elimination of glycopyrronium is severely impaired in patients with renal failure.

Please [click here](#) for Full Prescribing Information and visit QBREXZA.com for more information.